Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada
· manilatimes.net
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced the market launch of neffy® 2 mg in Canada following the approval by Health Canada in April 2026. The launch of this first ever nasal adrenaline spray for emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions due to insect stings or bites, foods, medicines and other allergens, as well as anaphylaxis where the cause is not known or anaphylaxis caused by exercise.
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced the market launch of neffy® 2 mg in Canada following the approval by Health Canada in April 2026. The ...